<DOC>
	<DOC>NCT01691300</DOC>
	<brief_summary>Positron emission tomography combined with computed tomography using carbon-11 acetate (ACT PET/CT) may help detect lesions before treatment and evaluate response following therapy in patients with from multiple myeloma (MM). This study aimed to prospectively assess the clinical utility of ACT PET/CT in MM as compared to the commonly used F18-fluorodeoxyglucose(FDG).</brief_summary>
	<brief_title>C11-Acetate PET/CT in Multiple Myeloma: Added Value to F18-Fluorodeoxyglucose PET/CT</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<criteria>at least 20 years of age previously untreated complete pretreatment clinical staging including bone marrow examination written informed consent to participate in the study concurrent active malignant tumor(s) pregnant or breast feeding women noncompliant to PET/CT or to MRI marked renal impairment (contraindicated for contrastenhanced MRI)</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>C11-acetate PET/CT</keyword>
	<keyword>Multiple myeloma</keyword>
	<keyword>Pretreatment staging</keyword>
	<keyword>Response assessment</keyword>
</DOC>